Nilotinib
- PDF / 169,365 Bytes
- 1 Pages / 595.245 x 841.846 pts (A4) Page_size
- 100 Downloads / 153 Views
1 S
Development of resistance in chronic myeloid leukaemia: case report In a case series, an 83-year-old man was described, who developed drug resistance during treatment with nilotinib for chronic myeloid leukaemia (CML). The man, who had CML, had received first line therapy with imatinib. Then, he was treated with second line therapy with nilotinib 300mg twice daily [route not stated] for six years. A deep molecular response was achieved with this treatment for 3 years. However, a sudden and significant increase in the BCR-ABL1 ratio (10%) was observed. Thereafter, a colony-forming cell (CFC) analysis of blood sample showed clonogenic cells of CFU-GM, BFU-E, CFU-Mix. Subsequent quantitative real-time reverse transcription-PCR (qRT-PCR) showed BCR-ABL1 mRNA expression, indicative development of nilotinib resistance (secondary resistance) [time to reaction onset not stated]. The man’s therapy with nilotinib was therefore switched to bosutinib. Turhan AG, et al. Evidence of BCR-ABL1-positive progenitor spread in blood during molecular recurrence after TKI discontinuation in chronic myeloid leukemia (CML). 803500384 Leukemia and Lymphoma 61: 1719-1723, No. 7, Jun 2020. Available from: URL: http://doi.org/10.1080/10428194.2020.1734593
0114-9954/20/1821-0001/$14.95 Adis © 2020 Springer Nature Switzerland AG. All rights reserved
Reactions 12 Sep 2020 No. 1821
Data Loading...
